返回 Agenda
Session Chair(s)
Marc Poitras, PHD, MBA
Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
Health Canada, Canada
Margaret Zimmermann
Manager, Patient Safety Section, Marketed Health Products Directorate
Health Canada , Canada
Speaker(s)
Overview of the Revised Guidance
Margaret Zimmerman
Health Canada (MHPD), Canada
Manager, Policy & Partnership, Marketed Health Products Directorate
Perspective from a Labeling Reviewer
Ana Nesic, MPHARM
Health Canada, Canada
Senior Regulatory Policy & Risk Management Advisor
Implementation of the Revised Guidance
Tharany Ganesh, MSC
AstraZeneca Canada Inc., Canada
Head, Regulatory Affairs